Clinical and Pathological Features in Hydrocarbon-Induced Parkinsonism
Ann Neurol 40:922-925, Pezzoli,G.,et al, 1996
Liquid Levodopa/Carbidopa Produces Significant Improvement in Motor Function without Dyskinesia Exacerbation
Neurol 47:1493-1495, Pappert,E.J.,et al, 1996
Restless Legs Syndrome:Clinicoetiologic Correlates
Neurol 47:1435-1441, Ondo,W.&Jankovic,J., 1996
Presynaptic Dopaminergic Deficits in Lesch-Nyhan Disease
NEJM 334:1568-1572, 16021996., Ernst,M.,et al, 1996
Childhood Leukemia:Central Nervous System Abnormalities During and After Treatment
AJNR 17:295-310, Chen,C-Y.,et al, 1996
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
The Effect of Deprenyl and Levodopa on the Progression of Parkinson's Disease
Ann Neurol 38:771-777, Olanow,C.W.,et al, 1995
Early Differential Diagnosis of Parkinson's Disease with F-flurodeoxyglucose and Positron Emission Tomography
Neurol 45:1995-2004, Eidelberg,D.,et al, 1995
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Comparative Study of Selegiline Plus L-Dopa-Carbidopa VS L-Dopa-Carbidopa Alone in Trtm of Parkinson's Disease
Ann Neurol 37:95-98, Brannan,T.&Yahr,M.D., 1995
Some Specific Clinical Features Differentiate Multiple System Atrophy (Striatonigral Variety) from Parkinson's Disease
Arch Neurol 52:294-298, Colosimo,C.,et al, 1995
Low-Dose Clozapine in the Treatment of Levodopa-Induced Mental Disturbances in Parkinson's Disease
Neurol 45:432-434, Rabey,J.M.,et al, 1995
Levorotatory Form of 5-Hydroxytryptophan in Friedreich's Ataxia
Arch Neurol 52:456-460, Trouillas,P.,et al, 1995
Double-Blind Study with Levorotatory form of Hydroxytryptophan in Pts with Degen Cerebellar Dis
Arch Neurol 52:451-455, 4401995., Wessel,K.,et al, 1995
Neuroleptic Drug Exposure and Treatment of Parkinsonism in the Elderly:A Case-Control Study
Am J Med 99:48-54, Avorn,J.,et al, 1995
The Eosinophilia-Myalgia Syndrome:Status of 205 Patients and Results of Treatment 2 Years After Onset
Ann Int Med 122:851-855, Hertzman,P.A.,et al, 1995
Dopamine, Dystonia, and the Deficient Co-Factor
Lancet 345:1130, Williams,A.C., 1995
A Greek-American Kindred with Autosomal Dominant, Levodopa-Responsive Parkinsonism and Anticipation
Ann Neurol 38:373-378, 3551995., Markopoulou,K.,et al, 1995
Multiple System Atrophy presenting as Parkinsonism:Clinical Features and Diagnostic Criteria
JNNP 59:144-151, Albanese,A.,et al, 1995
Occurrence of Different Cancers in Patients with Parkinson's Disease
BMJ 310:1500-1501, Moller,H.,et al, 1995
Psychosis in Advanced Parkinson's Disease:Treatment with Ondansetron, a 5-HT3 Receptor Antagonist
Neurol 45:1305-1308, Zoldan,J.,et al, 1995
Increased Incidence of Levodopa Therapy Following Metoclopramide Use
JAMA 274:1780-1782, Avorn,J.,et al, 1995
Dopa-Responsive parkinsonism Phenotype of Machado-Jospeh Disease:Confirmation of 14q CAG Expansion
Ann Neurol 48:684-687, Tuite,P.J.,et al, 1995
Levodopa Failure in Chronic Manganism
Neurol 44:1600-1602, 15831994., Lu,C-S.,et al, 1994
Dopa-Responsive Dystonia:Pathological and Biochemical Observations in a Case
Ann Neurol 35:396-402, 3811994., Rajput,A.H.,et al, 1994
A Multicenter Double-Blind Placebo-Controlled Trial of Pergolide as an Adjunct to Sinemet in Parkinson's Disease
Movement Disorders, 9:40-471994., Olanow,C.W.,et al, 1994
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Parkinsonism Induced by Solvent Abuse
Ann NEurol 35:616-618, Uitti,R.J.,et al, 1994
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
NEJM 330:613-622, Lipton,S.A.&Rosenberg,P.A., 1994
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
NEJM 330:585-591, Bensimon,G.,et al, 1994
Reverse Shapiro's Syndrome:Hirayama
K. , et al, Arch Neurol 51:494-49694., , 1994
Evidence for a Dopaminergic Deficit in Sporadic Amyoptrophic Lateral Sclerosis on Positron Emission Scanning
Lancet 324:1016-1018, Takahashi,H.,et al, 1993
Dopaminergic Treatment of Restless Legs and Rebound Phenomenon
Neurol 43:455, Guilleminault,C.,et al, 1993
A Clinicopathologic Study of 100 Cases of Parkinson's Disease
Arch Neurol 50:140-148, Hughes,A.J.,et al, 1993
Neurocognitive Dysfunction in the Eosinophilia-Myalgia Syndrome
Neurol 43:931-936, Krupp,L.B.,et al, 1993
Comparisons of Therapeutic Effects of Levodopa
Levodopa & Selegiline, & Bromocriptine in Pts with Early, Mild Parkinson's, Parkinson's Res Grp in U, , BMJ 372,1993., 1993
Levodopa, Melanoma, and Parkinson's Disease
Neurol 43:674-677, Weiner,W.J.,et al, 1993
Clinical Experience with Controlled-Release Carbidopa/Levodopa in Parkinson's Disease
Neurol 43:677-681, Pahwa,R.,et al, 1993
Levodopa Improves Spatial Contrast Sensitivity in Parkinson's Disease
Arch Neurol 50:721-724, Hutton,J.T.,et al, 1993
The Spectrum of Levodopa-Related Fluctuations in Parkinson's Disease
Neurol 43:1459-1464, Riley,D.E.&Lang,A.E., 1993
Blood Levodopa Levels and Unified Parkinson's Disease Rating Scale Function:With and Without Exercise
Neurol 43:1040-1042, Goetz,C.G.,et al, 1993
Periodic Triphasic Waves in Levodopa-Induced Encephalopathy
Neurol 42:444-446, Neufeld,M.Y., 1992
123I-iodobenzamide-SPECT Predicts Dopaminergic Responsiveness in patients with De Dovo Parkinsonism
Neurol 42:556-561, Schwarz,J.,et al, 1992
Gerstmann's Syndrome
Arch Neurol 49:445-447, Benton,A.L., 1992
Eosinophilia-Myalgia Syndrome, Natural History in a Population-Based Cohort
Arch Int Med 152:1889-1892, Hedberg,K.,et al, 1992
Chronic Demyelinating Polyneuropathy Associated with Eosinophilia-Myalgia Syndrome
JNNP 55:352-358, Freimer,M.L.,et al, 1992
Levodopa-Nonresponsive Lewy Body Parkinsonism:Clinicopathologic Study of Two Cases
Neurol 42:1323-1327, Mark,M.H.,et al, 1992
The Cause and pathogenesis of the Eosinophilia-Myalgia Syndrome
Ann Int Med 116:140-147, Varga,J.,et al, 1992
Eosinophilia-Myalgia Syndrome in L-Tryptophan-Exposed Patients
JAMA 267:77-82, Kamb,M.L.,et al, 1992
Acute Encephalopathy Associated with the Eosinophilia-Myalgia Syndrome
Neurol 42:461-462, Adair,J.C.,et al, 1992